
Superpower peptides available for pre-order. Get first access.

Not FDA-approved
Digestive & weight
AOD-9604
Also called hGH fragment 176-191
Key takeaway
AOD-9604 is a modified fragment of the tail end of human growth hormone, developed as a fat-loss drug. Its human obesity trials failed to beat placebo, and development for obesity was halted. As of 2026 it is not FDA-approved and is banned in sport.
- Written by
- Nav SekhonResearch Lead
- Published
- April 18, 2026
- Last updated
- October 5, 2026
At a glance
| FDA status | Non-FDA-approved peptide |
| What it is | Modified fragment of the growth hormone molecule, studied for fat loss |
| Research | Human obesity trials did not beat placebo, and development was discontinued |
| Sport | Prohibited by WADA at all times |
| Evidence strength | Low research |
What is AOD-9604?
AOD-9604 is a synthetic peptide based on the C-terminal (tail) region of human growth hormone, with an added amino acid to stabilize it. The name stands for "Advanced Obesity Drug," reflecting its original development by Metabolic Pharmaceuticals as a weight-loss candidate. It is sold on the wellness and "research peptide" market for fat loss, often under the broader "hGH fragment 176-191" label, though it is a modified version of that fragment rather than the bare fragment.
How does it work?
The proposed idea is that the tail region of growth hormone carries its fat-burning activity without the rest of the hormone's effects. In animal and cell studies, AOD-9604 increased both fat breakdown and fat oxidation while it reduced fat storage, reportedly without activating the growth hormone receptor or causing growth or insulin-resistance effects. In rodents, it also raised markers of fat metabolism (here1 and here2). These are animal and laboratory findings; the human trials below tested whether they translate.
Is it FDA-approved?
No. AOD-9604's regulatory status covers several points:
- Not approved by the FDA for any use, and never reached market as a drug
- A history that includes an attempt to position it as a food/supplement ingredient
- Not an approved compounding substance
- Prohibited at all times in sport under the WADA list, which covers growth hormone fragments including AOD-9604
What does the research show?
Unusually for a wellness peptide, AOD-9604 was tested in real human trials, and they were negative. A 24-week Phase 2b obesity trial of 536 participants did not produce significant weight loss3 versus placebo, and development for obesity was terminated in 2007; an earlier, smaller signal did not replicate. The supporting mechanism data remain animal and cell-based. So the best human evidence does not support the marketed fat-loss use; it argues against it.
More for digestive & weight
Sources: animal studies of the growth hormone fragment's fat-metabolism effects (Ng et al., Hormone Research, 2000, DOI: 10.1159/0000531831; Heffernan et al., International Journal of Obesity, 2001, DOI: 10.1038/sj.ijo.08017402), indexed on PubMed; reporting on the discontinued obesity program; and the WADA Prohibited List. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.